- Trials with a EudraCT protocol (2,070)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
2,070 result(s) found.
Displaying page 32 of 104.
EudraCT Number: 2020-001537-13 | Sponsor Protocol Number: ALXN1210-NEPH-202 | Start Date*: 2021-03-25 | ||||||||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Ne... | ||||||||||||||||||
Medical condition: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005758-36 | Sponsor Protocol Number: UTX-TGR-304 | Start Date*: 2016-10-28 | |||||||||||
Sponsor Name:TG Therapeutics | |||||||||||||
Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003809-60 | Sponsor Protocol Number: XPORT-MF-035 | Start Date*: 2021-07-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||||||||||||
Full Title: A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis | |||||||||||||||||||||||||||||||||
Medical condition: Myelofibrosis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Completed) PL (Temporarily Halted) GR (Completed) IT (Ongoing) ES (Temporarily Halted) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001565-33 | Sponsor Protocol Number: RA101495-02.302 | Start Date*: 2020-04-24 | |||||||||||
Sponsor Name:Ra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005932-50 | Sponsor Protocol Number: BCX7353-304 | Start Date*: 2022-10-05 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE | |||||||||||||
Medical condition: Hereditary Angioedema (HAE) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) IT (Ongoing) ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002491-10 | Sponsor Protocol Number: Alofisel-4001 | Start Date*: 2020-03-10 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula | |||||||||||||
Medical condition: Perianal fistulising Crohn´s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) FR (Ongoing) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003396-19 | Sponsor Protocol Number: EOADR1-19 | Start Date*: 2020-05-06 | |||||||||||||||||||||
Sponsor Name:Enterome | |||||||||||||||||||||||
Full Title: A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adr... | |||||||||||||||||||||||
Medical condition: - locally advanced or metastatic adrenocortical carcinoma (ACC) - malignant pheochromocytoma/paraganglioma (MPP) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) ES (Ongoing) DE (Ongoing) DK (Ongoing) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002301-24 | Sponsor Protocol Number: NMD670-02-0001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:NMD Pharma A/S | |||||||||||||
Full Title: A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy | |||||||||||||
Medical condition: Type 3 spinal muscular atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Ongoing) DE (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005297-10 | Sponsor Protocol Number: DCL-16-001 | Start Date*: 2021-05-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Cellectar Biosciences, Inc. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobu... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Part A: MM (multiple myeloma), CLL/SLL(chronic lymphocytic leukemia/small lymphocytic lymphoma), LPL/WM(lymphoplasmacytic lymphoma/ Waldenstrom's Macroglobulinemia), MZL(marginal zone lymphoma), MC... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) GR (Ongoing) FR (Ongoing) ES (Ongoing) FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003855-40 | Sponsor Protocol Number: MOR208C115 | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref... | |||||||||||||
Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) CZ (Trial now transitioned) IT (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001010-10 | Sponsor Protocol Number: CGT9486-20-201 | Start Date*: 2021-12-09 | |||||||||||
Sponsor Name:Cogent Biosciences, Inc. | |||||||||||||
Full Title: A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis | |||||||||||||
Medical condition: Advanced Systemic Mastocytosis (AdvSM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NO (Ongoing) IT (Ongoing) AT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003206-41 | Sponsor Protocol Number: LOXO-BTK-20030(J2N-OX-JZNU) | Start Date*: 2022-07-11 | |||||||||||
Sponsor Name:Loxo Oncology, Inc. | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) ES (Ongoing) IT (Ongoing) CZ (Trial now transitioned) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005744-29 | Sponsor Protocol Number: GCT3013-06 | Start Date*: 2022-10-06 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL, PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EPCORITAMAB (GEN3013; DUOBODY®-CD3×CD20) AS MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE AS FI... | |||||||||||||
Medical condition: B-cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Ongoing) CZ (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002529-12 | Sponsor Protocol Number: CICL670F2203 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis | |||||||||||||
Medical condition: Hereditary Hemochromatosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SK (Completed) DE (Completed) BE (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004590-51 | Sponsor Protocol Number: 233AS303 | Start Date*: 2021-09-15 | |||||||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed... | |||||||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) FR (Ongoing) BE (Completed) IT (Ongoing) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003136-25 | Sponsor Protocol Number: CTD-TCNPC-301 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:Cyclo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Double blind, Randomized, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl β cycl... | |||||||||||||
Medical condition: Niemann Pick Disease Type C1 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) PL (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004998-32 | Sponsor Protocol Number: ARGX-117-2003 | Start Date*: 2022-09-29 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Long-Term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerabillity, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Mult... | |||||||||||||
Medical condition: Multifocal Motor Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Ongoing) NL (Trial now transitioned) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004124-10 | Sponsor Protocol Number: 68284528MMY2003 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004313-39 | Sponsor Protocol Number: TCH-306EXT | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:Ascendis Pharma Endocrinology Division A/S | |||||||||||||
Full Title: A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) SK (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005733-16 | Sponsor Protocol Number: DNLI-H-0001 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Denali Therapeutics Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in ... | |||||||||||||
Medical condition: Frontotemporal Dementia (FTD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) PT (Ongoing) CZ (Completed) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.